Most recent update: Wednesday, November 13, 2019 - 09:43

Bariatric News - Cookies & privacy policy

You are here

type 2 diabetes mellitus

Obesity linked to a six-fold increased risk of T2DM

Obesity is linked to a nearly 6-fold increased risk of developing type 2 diabetes mellitus (T2DM), with high genetic risk and unfavourable lifestyle also increasing risk but to a much lesser extent, according to research presented at the Annual Meeting of the European Association for the Study of Diabetes in Barcelona, Spain by Hermina Jakupovic, University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen, Denmark, and colleagues.

IL-36 cytokines proteins associated with better T2DM control

Scientists from the School of Medicine, Trinity College Dublin, have discovered a family of proteins that are associated with lower blood sugar levels among obese patients with type 2 diabetes. The study showed that patients with type 2 diabetes who have high levels of the protein, IL-36 cytokines, were found to have lower blood sugar levels, implying that those proteins are associated with better control of the patient's blood sugar levels and their disease.

Short stature is associated with higher risk of T2DM

Short stature is associated with a higher risk of type 2 diabetes and tall stature is associated with a lower risk, with each 10cm difference in height associated with a 41% decreased risk of diabetes in men and a 33% decreased risk in women, according to researchers from the German Institute of Human Nutrition Potsdam-Rehbruecke, Germany.

Three POCs to become early adopters of the Low Carb Program

Three primary care organisations (POCs) in the UK, have been announced as joint winners of a competition to enable healthcare professionals to offer free access to an award-winning behaviour change platform, the Low Carb Program, for a select group of their patients living with Type 2 diabetes. The organisations were named as: Frome Medical Practice (on behalf of Your Health & Wellbeing collaboration of three Primary Care Networks) in Frome, Somerset; Park Medical Centre in London and Freshwell Health Centre in Braintree, Essex.

Changes to mitochondria drive chronic inflammation linked to T2DM

The underlying causes of inflammation in obesity and type 2 diabetes mellitus (T2DM) are multifactorial and complex, which has hampered efforts to develop treatments to prevent complications from a disease that is the third leading cause of death in the US. Researchers at the University of Kentucky have reported that changes to mitochondria drive chronic inflammation from cells exposed to certain types of fats, shattering the prevailing assumption that glucose was the culprit.

Researchers investigate autophagy’s role in metabolic disease

Researchers at the University of Florida are investigating how autophagy - the body's way of cleaning out damaged cells, in order to regenerate newer, healthier cells - plays a role in metabolic diseases such as obesity and type 2 diabetes.

Vitamin D supplementation may slow diabetes progression

Vitamin D supplementation may slow the progression of type 2 diabetes in newly diagnosed patients and those with pre-diabetes, suggesting that high-dose supplementation of vitamin D can improve glucose metabolism to help prevent the development and progression of diabetes.

Gene associated with obesity and T2DM cells fat regulation

Researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts (HNRCA) have found one clue as to why weight gain cause metabolic problems that can lead to heart disease and diabetes in some individuals, but not others: a gene associated with obesity and development of type 2 diabetes, they discovered, is also connected to how cells regulate fat at the cellular level.

Bariatric surgery reduces spending on T2DM and hypertension meds

Patients with severe obesity who undergo bariatric surgery cut their spending on diabetes medications by nearly 65 percent and spending on high blood pressure medications by more than a third three to six months after the operation, according to new research from Rush Medical College in Chicago presented at an American Society for Metabolic and Bariatric Surgery (ASMBS) national clinical symposium on obesity prevention, treatment and research.

Invokana reduces MACE and kidney failure in T2DM patients

The results of a new subgroup analysis from the landmark Phase III CREDENCE study shows Invokana (canagliflozin) significantly reduced the risk of major cardiovascular (CV) events and kidney failure in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in patients with and without known cardiovascular (CV) disease. The results were presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco.

Subscribe to RSS - type 2 diabetes mellitus